IL18 and chronic inflammatory demyelinating polyradiculoneuropathy: In this context, IL18 promoter genotypes and haplotypes can be viewed as generic immune-response modifiers rather than disease-specific mutations, providing a biologically grounded rationale to investigate their influence on demyelinating and barrier-related phenotypes even in a rare neuroimmune disorder such as CIDP (Ihim et al., 2022; Dziedziejko et al., 2012; Ramezanzadeh et al., 2024).